adamis pharmaceuticals corp (ADMP) Key Developments
ADMP Eyes Acquisitions
Jan 8 15
Adamis Pharmaceuticals Corporation (NasdaqCM:ADMP) is looking for acquisition opportunities. ADMP announced that it intends to offer shares of its common stock in an underwritten public offering. ADMP intends to use the net proceeds of the offering for general corporate purposes, which include, without limitation, hiring additional personnel and other expenditures relating to the company's anticipated commercial launch of its Epinephrine PFS syringe product (if the FDA grants marketing approval for the product), research and development and clinical trial expenditures, acquisitions of new technologies or products, the repayment, refinancing, redemption or repurchase of future indebtedness or capital stock and working capital.
Adamis Pharmaceuticals Corporation Presents at Oppenheimer 25th Annual Healthcare Conference, Dec-10-2014 03:20 PM
Dec 2 14
Adamis Pharmaceuticals Corporation Presents at Oppenheimer 25th Annual Healthcare Conference, Dec-10-2014 03:20 PM. Venue: The Crowne Plaza Hotel, New York, New York, United States.
Adamis Pharmaceuticals Corporation Presents at LD Micro Conference, Dec-03-2014 10:00 AM
Nov 5 14
Adamis Pharmaceuticals Corporation Presents at LD Micro Conference, Dec-03-2014 10:00 AM. Venue: Luxe Sunset Boulevard Hotel, 11461 Sunset Boulevard, Los Angeles, California, United States.
Adamis Pharmaceuticals Corporation Announces Executive Appointments
Oct 15 14
Adamis Pharmaceuticals Corporation announced additions to its medical and product marketing management teams. Dragana Males, M.D. has joined Adamis as a Medical Director. In this role, she will work closely with other senior management members to oversee all aspects of clinical development. Most recently, she served as Drug Safety Physician within the Medical Services Group of Product Safety and Risk Management at Mylan Inc. Jennifer C. Suski has joined Adamis as Senior Director of Marketing. Most recently, she was Director of Marketing for Santarus Inc. Joshua D. Seno has also joined Adamis from Santarus as Senior Director of Commercial Affairs bringing over 12 years of commercial experience with him. In his last role, was Director of Market Research & Forecasting for Santarus Inc.
Adamis Pharmaceuticals Corporation, Annual General Meeting, Nov 06, 2014
Oct 9 14
Adamis Pharmaceuticals Corporation, Annual General Meeting, Nov 06, 2014., at 10:00 Pacific Daylight. Location: 11682 El Camino Real, Suite 300. Agenda: To elect five directors to the Board of Directors to serve until the next Annual Meeting of Stockholders or until their successors have been duly elected or appointed and qualified; to approve amendments to the company’s 2009 Equity Incentive Plan to increase by 1,000,000 shares the number of shares authorized for issuance there under, and to make certain other changes to the Plan as described in more detail in the Proxy Statement; to approve, on a nonbinding advisory basis, the compensation of the named executive officers; to ratify the selection of Mayer Hoffman McCann PC as the independent registered public accounting firm for the year ending March 31, 2015; and to transact such other business as may properly come before the Meeting or any adjournments or postponements thereof.